Elexacaftor: all 23 studies that test it

Page 1 of 1. Open to participants first (2), then studies with results posted, then the rest; newest registration first within each.

• Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor in Cystic FibrosisRecruitingNCT07809867Phase 4
• Ensuring Access to Optimal Therapy in CF: The ENACT StudyRecruitingNCT07148739Phase 4
• Evaluation of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis (CF) Participants 12 to Less Than 24 Months of AgeCompletedNCT05882357Phase 3Results posted
• Evaluation of Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis Subjects Without an F508del MutationCompletedNCT05274269Phase 3Results posted
• A Study Evaluating the Safety of Elexacaftor/Tezacaftor/Ivacaftor in Participants With Cystic Fibrosis (CF)CompletedNCT05111145Phase 3Results posted
• A Study to Evaluate ELX/TEZ/IVA on Cough and Physical Activity in Participants With Cystic Fibrosis (CF)CompletedNCT04969224Phase 3Results posted
• A Study to Assess the Effect of ELX/TEZ/IVA on Glucose Tolerance in Participants With Cystic Fibrosis (CF)CompletedNCT04599465Phase 3Results posted
• A Study Evaluating the Long-term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis (CF) Particpants 6 Years and Older and F/MF GenotypesCompletedNCT04545515Phase 3Results posted
• Evaluation of ELX/TEZ/IVA in Cystic Fibrosis (CF) Subjects 2 Through 5 YearsCompletedNCT04537793Phase 3Results posted
• A Study Evaluating the Long-Term Safety of Elexacaftor Combination TherapyCompletedNCT04362761Phase 3Results posted
• A Study Evaluating Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis and F/MF GenotypesCompletedNCT04353817Phase 3Results posted
• Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA TC Combination Therapy in Participants With Cystic Fibrosis Who Are 6 Years of Age and OlderCompletedNCT04183790Phase 3Results posted
• A Study Evaluating the Efficacy and Safety of VX-445/Tezacaftor/Ivacaftor in Cystic Fibrosis Subjects, Homozygous for F508delCompletedNCT04105972Phase 3Results posted
• Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination TherapyCompletedNCT04058366Phase 3Results posted
• A Phase 3 Study of VX-445 Combination Therapy in Cystic Fibrosis (CF) Subjects Heterozygous for F508del and a Gating or Residual Function Mutation (F/G and F/RF Genotypes)CompletedNCT04058353Phase 3Results posted
• A Study Evaluating the Long-term Safety of VX-445 Combination TherapyCompletedNCT04043806Phase 3Results posted
• Evaluation of VX 445/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of AgeCompletedNCT03691779Phase 3Results posted
• A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination TherapyCompletedNCT03525574Phase 3Results posted
• A Study of VX-445 in Healthy Subjects and Subjects With Cystic FibrosisCompletedNCT03227471Phase 1/2Results posted
• Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and OlderActive, not recruitingNCT06460506Phase 3
• Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508delActive, not recruitingNCT05331183Phase 3
• Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis (CF) Participants 2 Years and OlderCompletedNCT05153317Phase 3
• Real World Clinical Outcomes With Novel Modulator Therapy Combinations in People With CF (RECOVER)Active, not recruitingNCT04602468Phase 4

← Elexacaftor overview